JP2019524671A - 抗ｃｄ１９抗体製剤 - Google Patents

抗ｃｄ１９抗体製剤 Download PDF

Info

Publication number
JP2019524671A
JP2019524671A JP2018567742A JP2018567742A JP2019524671A JP 2019524671 A JP2019524671 A JP 2019524671A JP 2018567742 A JP2018567742 A JP 2018567742A JP 2018567742 A JP2018567742 A JP 2018567742A JP 2019524671 A JP2019524671 A JP 2019524671A
Authority
JP
Japan
Prior art keywords
concentration
formulation
antibody
polysorbate
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018567742A
Other languages
English (en)
Japanese (ja)
Inventor
ガリデル，パトリック
ランゲル，アンドレアス
ヘスリング，マルティン
ヴァインフルトナー，ダニエル
ブロックス，ボド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MorphoSys GmbH
Original Assignee
MorphoSys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MorphoSys GmbH filed Critical MorphoSys GmbH
Publication of JP2019524671A publication Critical patent/JP2019524671A/ja
Priority to JP2022081779A priority Critical patent/JP7603201B2/ja
Priority to JP2024083988A priority patent/JP2024109816A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2018567742A 2016-06-27 2017-06-27 抗ｃｄ１９抗体製剤 Pending JP2019524671A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022081779A JP7603201B2 (ja) 2016-06-27 2022-05-18 抗ｃｄ１９抗体製剤
JP2024083988A JP2024109816A (ja) 2016-06-27 2024-05-23 抗ｃｄ１９抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16176322.2 2016-06-27
EP16176322 2016-06-27
PCT/EP2017/065819 WO2018002031A1 (en) 2016-06-27 2017-06-27 Anti-cd19 antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022081779A Division JP7603201B2 (ja) 2016-06-27 2022-05-18 抗ｃｄ１９抗体製剤

Publications (1)

Publication Number Publication Date
JP2019524671A true JP2019524671A (ja) 2019-09-05

Family

ID=56368805

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018567742A Pending JP2019524671A (ja) 2016-06-27 2017-06-27 抗ｃｄ１９抗体製剤
JP2022081779A Active JP7603201B2 (ja) 2016-06-27 2022-05-18 抗ｃｄ１９抗体製剤
JP2024083988A Pending JP2024109816A (ja) 2016-06-27 2024-05-23 抗ｃｄ１９抗体製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022081779A Active JP7603201B2 (ja) 2016-06-27 2022-05-18 抗ｃｄ１９抗体製剤
JP2024083988A Pending JP2024109816A (ja) 2016-06-27 2024-05-23 抗ｃｄ１９抗体製剤

Country Status (26)

Country Link
US (2) US11352423B2 (enExample)
EP (2) EP3909985A1 (enExample)
JP (3) JP2019524671A (enExample)
KR (2) KR102533875B1 (enExample)
CN (2) CN115998859A (enExample)
AU (2) AU2017289085B2 (enExample)
CA (1) CA3029137A1 (enExample)
CY (1) CY1124521T1 (enExample)
DK (1) DK3475303T3 (enExample)
ES (1) ES2874640T3 (enExample)
HR (1) HRP20210945T1 (enExample)
HU (1) HUE054296T2 (enExample)
IL (1) IL263764B2 (enExample)
LT (1) LT3475303T (enExample)
MA (1) MA45450B1 (enExample)
MD (1) MD3475303T2 (enExample)
MX (1) MX2018016362A (enExample)
PL (1) PL3475303T3 (enExample)
PT (1) PT3475303T (enExample)
RS (1) RS62035B1 (enExample)
RU (1) RU2748024C2 (enExample)
SG (2) SG10201912369QA (enExample)
SI (1) SI3475303T1 (enExample)
SM (1) SMT202100317T1 (enExample)
WO (1) WO2018002031A1 (enExample)
ZA (1) ZA201900483B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
LT3532098T (lt) 2016-10-28 2021-06-25 Morphosys Ag Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
AU2020372646A1 (en) 2019-10-31 2022-05-12 Incyte Corporation Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells
JP2023530499A (ja) 2020-06-22 2023-07-18 モルフォシス・アーゲー 抗ＣＤ１９抗体及びＳＩＲＰα－ＣＤ４７自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
EP4426439A1 (en) 2021-11-03 2024-09-11 Affimed GmbH Bispecific cd16a binders
AU2023264582A1 (en) * 2022-05-03 2024-11-21 Incyte Corporation Methods for treating lymphoma
EP4572756A1 (en) 2022-08-17 2025-06-25 Incyte Corporation Therapy comprising anti-cd19 antibody and ezh2 modulators
IL322510A (en) * 2023-03-02 2025-10-01 Novetide Ltd Method for preparing GLP-1 peptides with controlled particle size
CN120754244B (zh) * 2025-09-10 2025-12-12 江苏豪森药业集团有限公司 一种含抗cd19抗体的药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500882A (ja) * 2006-08-14 2010-01-14 ゼンコー・インコーポレイテッド Ｃｄ１９を標的とする最適化抗体
WO2015157286A1 (en) * 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
ATE395413T1 (de) 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
LT2176298T (lt) 2007-05-30 2018-04-10 Xencor, Inc. Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
JP2012519712A (ja) * 2009-03-06 2012-08-30 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体製剤
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014160490A1 (en) 2013-03-13 2014-10-02 Genetech, Inc. Antibody formulations
RU2707092C2 (ru) 2013-03-13 2019-11-22 Дженентек, Инк. Составы со сниженным окислением
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
LT3049441T (lt) 2013-09-27 2020-02-10 F. Hoffmann-La Roche Ag Anti-pdl1 antikūnų kompozicija
JP6590803B2 (ja) * 2013-11-21 2019-10-16 ゲンマブ エー／エス 抗体−薬物コンジュゲート凍結乾燥製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500882A (ja) * 2006-08-14 2010-01-14 ゼンコー・インコーポレイテッド Ｃｄ１９を標的とする最適化抗体
WO2015157286A1 (en) * 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLELAND J L: "A SPECIFIC MOLAR RATIO OF STABILIZER TO PROTEIN IS REQUIRED FOR STORAGE STABILITY OF A 以下備考", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. VOL:90, NR:3, JPN5019006016, March 2001 (2001-03-01), US, pages 310 - 321, ISSN: 0004684287 *
CONNOLLY BRIAN D: "PROTEIN AGGREGATION IN FROZEN TREHALOSE FORMULATIONS: EFFECTS OF COMPOSITION, COOLING RATE, 以下備考", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. VOL:104, NR:12, JPN5019006017, December 2015 (2015-12-01), US, pages 4170 - 4184, ISSN: 0004684286 *
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 185, JPN6021020280, 1999, pages 129 - 188, ISSN: 0004684289 *
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 91(4), JPN6021020276, 2002, pages 914 - 922, ISSN: 0004684285 *
ZHOU CHEN: "REDUCED SUBVISIBLE PARTICLE FORMATION IN LYOPHILIZED INTRAVENOUS IMMUNOGLOBULIN 以下備考", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. VOL:105, NR:8, JPN5019006015, 9 June 2016 (2016-06-09), pages 2302 - 2309, ISSN: 0004684288 *

Also Published As

Publication number Publication date
ZA201900483B (en) 2021-06-30
AU2017289085B2 (en) 2024-07-18
WO2018002031A1 (en) 2018-01-04
IL263764B1 (en) 2024-05-01
CN115998859A (zh) 2023-04-25
ES2874640T3 (es) 2021-11-05
NZ748681A (en) 2025-06-27
KR20190021373A (ko) 2019-03-05
KR20230074823A (ko) 2023-05-31
IL263764B2 (en) 2024-09-01
EP3475303B1 (en) 2021-04-14
HUE054296T2 (hu) 2021-08-30
EP3909985A1 (en) 2021-11-17
HRP20210945T1 (hr) 2021-09-17
PT3475303T (pt) 2021-06-25
RU2019100221A3 (enExample) 2020-11-30
AU2024205042A1 (en) 2024-08-15
MD3475303T2 (ro) 2021-09-30
MX2018016362A (es) 2019-04-22
AU2017289085A1 (en) 2018-12-13
SMT202100317T1 (it) 2021-07-12
US11352423B2 (en) 2022-06-07
CA3029137A1 (en) 2018-01-04
CN109415440A (zh) 2019-03-01
LT3475303T (lt) 2021-06-25
SG11201810429UA (en) 2018-12-28
IL263764A (en) 2019-01-31
SG10201912369QA (en) 2020-02-27
RS62035B1 (sr) 2021-07-30
SI3475303T1 (sl) 2021-12-31
RU2019100221A (ru) 2020-07-28
US20220213190A1 (en) 2022-07-07
KR102533875B1 (ko) 2023-05-18
CN109415440B (zh) 2022-12-06
CY1124521T1 (el) 2022-07-22
EP3475303A1 (en) 2019-05-01
PL3475303T3 (pl) 2021-12-06
MA45450B1 (fr) 2021-04-30
US20190322742A1 (en) 2019-10-24
JP7603201B2 (ja) 2024-12-20
DK3475303T3 (da) 2021-05-31
JP2022119854A (ja) 2022-08-17
RU2748024C2 (ru) 2021-05-19
JP2024109816A (ja) 2024-08-14

Similar Documents

Publication Publication Date Title
JP7603201B2 (ja) 抗ｃｄ１９抗体製剤
IL275038B2 (en) Formulation for anti-antibody alpha 4 in cell 7
US11498961B2 (en) SOST antibody pharmaceutical composition and uses thereof
CN110732023A (zh) 一种her2抗体药物组合物及其用途
CA3105360A1 (en) Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer
WO2020108621A1 (zh) 一种cd40抗体药物组合物及其用途
HK40064043A (en) Anti-cd19 antibody formulations
RU2848327C1 (ru) Составы на основе антитела к CD19
HK40004579B (en) Anti-cd19 antibody formulations
HK40004579A (en) Anti-cd19 antibody formulations
HK40004117B (zh) 抗-cd19抗体制剂
HK40004117A (en) Anti-cd19 antibody formulations
NZ789731A (en) Anti-CD19 antibody formulations
WO2024083074A1 (en) Formulations containing anti-tigit antibody and methods of use thereof
JP2025515325A (ja) 抗ｉｌｔ４抗体又はその抗原結合フラグメントの医薬製剤及び使用方法
WO2025108438A1 (zh) 抗her3抗体药物偶联物和抗vegf抗体治疗肿瘤的方法
WO2025162364A1 (zh) 抗CD79b抗体药物偶联物联合免疫治疗剂、化疗剂治疗肿瘤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220118